Preclinical evaluation of pharmacokinetics and safety of melatonin in propylene glycol for intravenous administration
- 21 August 2006
- journal article
- Published by Wiley in Journal of Pineal Research
- Vol. 41 (4), 337-343
- https://doi.org/10.1111/j.1600-079x.2006.00372.x
Abstract
Melatonin is a highly effective treatment in different animal models of excitotoxicity or ischemia/reperfusion injury. Due to a lack of patentability, commercial sponsors are not interested in funding clinical evaluations of melatonin. Investigators may initiate small-scale clinical evaluation, and intravenous (i.v.) administration is appropriate in acute stroke patients. Institutional Review Boards may require proper preclinical evaluation of the preparation. In this pharmacokinetic and safety study, melatonin in propylene glycol was evaluated in adult male Sprague-Dawley rats. Following a single i.v. injection at 5 or 15 mg/kg, plasma concentrations of melatonin increased to 39 and 199 million pg/mL at 2 min and 128 000 and 772 000 pg/mL at 120 min. Within 60 min of injection, the blood pressure, heart rate and body temperature remained unaffected. Melatonin at 5 mg/kg did not influence the complete blood counts at 60 min, but melatonin at 15 mg/kg had some effects on the differential white cell and platelet counts. Melatonin at 5 or 15 mg/kg slightly elevated some liver enzymes at 60 min of injection, and melatonin at higher dose also elevated plasma creatinine and lactate dehydrogenase levels. At 24 hr after completion of six daily injections of melatonin, there was a 5.5% reduction in body weight. Gross postmortem examination and histological examination of the brain, kidney, liver and spleen did not reveal any evidence of toxicity. In conclusion, melatonin in propylene glycol markedly elevates plasma levels of melatonin with no serious toxicity. This preparation should be further evaluated in human patients. © 2006 The Authors.link_to_subscribed_fulltexKeywords
This publication has 27 references indexed in Scilit:
- Melatonin reduces infarction volume in a photothrombotic stroke model in the wild‐type but not cyclooxygenase‐1‐gene knockout miceJournal of Pineal Research, 2006
- New toxicity data for the propylene glycol ethers – a commitment to public health and safetyToxicology Letters, 2005
- Tissue‐plasminogen activator‐induced ischemic brain injury is reversed by melatonin: role of iNOS and AktJournal of Pineal Research, 2005
- Melatonin attenuates gray and white matter damage in a mouse model of transient focal cerebral ischemiaJournal of Pineal Research, 2004
- Prophylactic use of melatonin protects against focal cerebral ischemia in mice: role of endothelin converting enzyme‐1Journal of Pineal Research, 2004
- Melatonin Ameliorates Neurologic Damage and Neurophysiologic Deficits in Experimental Models of StrokeAnnals of the New York Academy of Sciences, 2003
- Administration of Melatonin After Onset of Ischemia Reduces the Volume of Cerebral Infarction in a Rat Middle Cerebral Artery Occlusion Stroke ModelStroke, 2003
- Role of CSF in the transport of melatoninJournal of Pineal Research, 2002
- Diurnal Sensitivity in Melatonin-lnduced Hematological Changes in the Male Albino RatNeurosignals, 1996
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995